BidaskClub lowered shares of United Therapeutics (NASDAQ:UTHR) from a hold rating to a sell rating in a research report released on Tuesday, BidAskClub reports.

A number of other brokerages have also commented on UTHR. Wedbush reaffirmed a buy rating and set a $273.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. ValuEngine raised shares of United Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Credit Suisse Group raised shares of United Therapeutics from a neutral rating to an outperform rating and upped their price objective for the company from $98.00 to $101.00 in a research report on Monday, July 1st. UBS Group raised shares of United Therapeutics from a sell rating to a neutral rating and cut their price objective for the company from $115.00 to $94.00 in a research report on Friday, May 17th. They noted that the move was a valuation call. Finally, LADENBURG THALM/SH SH raised shares of United Therapeutics from a neutral rating to a buy rating and upped their price objective for the company from $103.00 to $106.00 in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. United Therapeutics presently has an average rating of Hold and an average price target of $120.36.

Shares of UTHR opened at $79.82 on Tuesday. The company has a 50-day simple moving average of $80.73 and a 200-day simple moving average of $93.03. The firm has a market capitalization of $3.64 billion, a P/E ratio of 5.96 and a beta of 0.92. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.41 and a current ratio of 4.62. United Therapeutics has a 52 week low of $74.31 and a 52 week high of $129.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $4.66 EPS for the quarter, beating the Zacks’ consensus estimate of $2.40 by $2.26. The business had revenue of $373.60 million during the quarter, compared to analyst estimates of $331.78 million. United Therapeutics had a negative net margin of 7.69% and a negative return on equity of 4.54%. As a group, equities analysts forecast that United Therapeutics will post -1.96 earnings per share for the current year.

In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $76.11, for a total transaction of $285,412.50. Following the sale, the director now directly owns 3,750 shares of the company’s stock, valued at $285,412.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard Giltner sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $79.05, for a total transaction of $395,250.00. Following the sale, the director now directly owns 5,000 shares in the company, valued at $395,250. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in United Therapeutics by 1.1% during the first quarter. BlackRock Inc. now owns 4,994,759 shares of the biotechnology company’s stock worth $586,236,000 after buying an additional 52,760 shares during the last quarter. Vanguard Group Inc. grew its stake in United Therapeutics by 0.8% during the second quarter. Vanguard Group Inc. now owns 3,988,515 shares of the biotechnology company’s stock worth $311,343,000 after buying an additional 33,194 shares during the last quarter. Renaissance Technologies LLC grew its stake in United Therapeutics by 35.7% during the second quarter. Renaissance Technologies LLC now owns 3,040,978 shares of the biotechnology company’s stock worth $237,379,000 after buying an additional 799,200 shares during the last quarter. First Trust Advisors LP grew its stake in United Therapeutics by 7.8% during the first quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock worth $151,477,000 after buying an additional 93,786 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in United Therapeutics by 2.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,982 shares of the biotechnology company’s stock worth $118,583,000 after buying an additional 29,427 shares during the last quarter. 94.16% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What is Elliott Wave theory?

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.